In the challenging battle against glioblastoma multiforme (GBM), a 35-year-old female patient from Europe faced a relentless progression of the disease despite undergoing surgery. However, a new ray of hope emerged as she was referred to(ECCT by her oncologist, combined with Bevacizumab during radiochemotherapy with temozolomide to fight gbm.
在与多形性胶质母细胞瘤（GBM）的激烈战斗中，一位来自欧洲的35岁女性患者尽管接受了手术，但仍然面临着疾病的无情进展。然而，当她被肿瘤科医生推荐接受电癌症惊厥疗法（ECCT）并结合贝伐单抗在放射化疗与替莫唑胺治疗期间时，一线希望出现了。
The patient embarked on a treatment regimen comprising ECCT sessions five days a week, complemented by Bevacizumab infusions at a dosage of 10mg/m2 every 14 days. This innovative approach aimed to curb the aggressive nature of GBM and halt its advancement.
患者开始了每周五天的ECCT疗程，同时结合贝伐单抗输液，剂量为10mg/m2，每14天一次。这一创新性的方法旨在遏制GBM的侵略性并阻止其进展。
The results were promising. By initiating ECCT right after the radiochemotherapy routine, the patient experienced a significant delay in tumor progression and recurrence. This dual treatment strategy, combining ECCT with Bevacizumab, showcased a positive impact on impeding the relentless nature of GBM.
结果是令人鼓舞的。通过在放射化疗常规之后立即启动ECCT，患者经历了肿瘤进展和复发的显著延迟。这种结合ECCT与贝伐单抗的双重治疗策略展示了对抗GBM无情本质的积极影响。
This case highlights the importance of collaboration between conventional therapies and innovative treatments like ECCT and Bevacizumab offers a glimpse of optimism for patients navigating the challenges posed by GBM.
这个案例突显了传统治疗与ECCT和贝伐单抗等创新治疗之间合作的重要性，为面对GBM挑战的患者提供了一线乐观。In the realm of GBM treatment, the integration of cutting-edge therapies provides not only hope but also tangible progress towards delaying disease progression. The journey of this 35-year-old patient serves as a testament to the ongoing efforts in medical research and patient care, ultimately paving the way for more effective treatments and improved outcomes in the fight against GBM.
在GBM治疗领域，先进疗法的整合不仅提供了希望，还实实在在地推动了疾病进展的延缓。这位35岁患者的旅程是对医学研究和患者护理不懈努力的证明，最终为在与GBM的斗争中提供更有效的治疗和改善结果铺平了道路。
Comments